Don't miss out on Wednesday 6th November 2024, when Arcus Biosciences (NYSE: RCUS) will disclose its third quarter financial results after market close. Investors will have the chance to learn more about the company's performance during the quarter.
According to the predictions of financial experts on Wall Street, the organization is set to unveil an estimated $1.06 loss per share for the quarter. Additionally, the company is expected to report a total revenue of $37.56 million for the specific period.
The company's yearly performance has been analyzed by Wall Street analysts, who have projected a total revenue of $252.41 million. Moreover, they anticipate the company to disclose loss of $3.22 per share for the fiscal year.
The company's earnings report for the corresponding quarter of the previous year showcased a per-share loss of $0.94. This figure was a result of the company's total revenue, which reached an impressive $32 million million during that specific period.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-1.02 | +1.9% | 39.00 M | +34.5% |
| Q1 2024 | $-0.05 | +95.4% | 145.00 M | +480.0% |
| Q4 2023 | $-1.08 | -16.1% | 31.00 M | -8.8% |
| Q3 2023 | $-0.94 | -4.4% | 32.00 M | -4.7% |
| Q2 2023 | $-1.04 | -11.8% | 29.00 M | +8.4% |
| *Growth on year-over-year basis | ||||
RCUS will host a conference call with investment community on 6th November 2024 at 05:00 PM eastern time to discuss the financial results.
Arcus Biosciences (RCUS) shares experienced a range of $15.19 to $15.78 on a day volume of 814.30 thousand shares. The stock closed Friday's regular trading session at $15.50, marking a 1.31 percent increase.
